276,485 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Purchased by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC purchased a new stake in Arbutus Biopharma Co. (NASDAQ:ABUSGet Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 276,485 shares of the biopharmaceutical company’s stock, valued at approximately $1,076,000. Quinn Opportunity Partners LLC owned about 0.20% of Arbutus Biopharma as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in shares of Arbutus Biopharma by 10,089.4% in the 2nd quarter. Royal Bank of Canada now owns 58,895 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 58,317 shares during the period. Invesco Ltd. purchased a new stake in Arbutus Biopharma in the second quarter worth approximately $76,000. BlackRock Inc. boosted its holdings in Arbutus Biopharma by 1.7% in the third quarter. BlackRock Inc. now owns 5,935,203 shares of the biopharmaceutical company’s stock worth $25,463,000 after purchasing an additional 99,630 shares during the last quarter. Barclays PLC raised its position in Arbutus Biopharma by 6,310.3% in the third quarter. Barclays PLC now owns 635,456 shares of the biopharmaceutical company’s stock worth $2,726,000 after acquiring an additional 625,543 shares during the period. Finally, Citigroup Inc. raised its position in Arbutus Biopharma by 53.5% in the third quarter. Citigroup Inc. now owns 14,679 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 5,117 shares during the period. 26.66% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of Arbutus Biopharma in a research note on Thursday, March 31st. They set a “hold” rating for the company. Jefferies Financial Group raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating and raised their target price for the company from $4.00 to $5.00 in a research note on Wednesday, February 2nd. Zacks Investment Research cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. HC Wainwright lifted their price objective on shares of Arbutus Biopharma from $8.00 to $8.50 and gave the stock a “buy” rating in a research note on Monday, March 14th. Finally, Chardan Capital lifted their price objective on shares of Arbutus Biopharma from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Friday, March 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Arbutus Biopharma presently has a consensus rating of “Buy” and an average target price of $6.25.

ABUS stock opened at $2.48 on Friday. The firm’s fifty day simple moving average is $2.60 and its 200-day simple moving average is $3.10. Arbutus Biopharma Co. has a 12 month low of $1.93 and a 12 month high of $6.50.

Arbutus Biopharma (NASDAQ:ABUSGet Rating) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $12.58 million during the quarter, compared to analysts’ expectations of $5.77 million. Arbutus Biopharma had a negative net margin of 352.49% and a negative return on equity of 121.30%. During the same period in the previous year, the business posted ($0.21) EPS. On average, research analysts expect that Arbutus Biopharma Co. will post -0.51 EPS for the current fiscal year.

Arbutus Biopharma Profile (Get Rating)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.

Featured Articles

Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.